# Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

> **NCT05492695** · PHASE4 · TERMINATED · sponsor: **Diamond Headache Clinic** · enrollment: 2 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Galcanezumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05492695
- **Lead sponsor:** Diamond Headache Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-01
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Stopped from financial sponsor due to inability to enroll participants.
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05492695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05492695, "Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05492695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*